Traci Medford-Rosow

While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.

On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case.